17 research outputs found

    TEDDI : radiotherapy delivery in deep inspiration for pediatric patients - a NOPHO feasibility study

    Get PDF
    Background: Radiotherapy (RT) delivered in deep inspiration breath-hold (DIBH) is a simple technique, in which changes in patient anatomy can significantly reduce the irradiation of the organs at risk (OARs) surrounding the treatment target. DIBH is routinely used in the treatment of some adult patients to diminish the risk of late effects; however, no formalized studies have addressed the potential benefit of DIBH in children. Methods/Design: TEDDI is a multicenter, non-randomized, feasibility study. The study investigates the dosimetric benefit of RT delivered in DIBH compared to free breathing (FB) in pediatric patients. Also, the study aims to establish the compliance to DIBH and to determine the accuracy and reproducibility in a pediatric setting. Pediatric patients (aged 5-17 years) with a tumor in the mediastinum or upper abdomen with the possible need of RT will be included in the study. Written informed consent is obligatory. Prior to any treatment, patients will undergo a DIBH training session followed by a diagnostic PET/CT-or CT-staging scan in both DIBH and FB. If the patient proceeds to RT, a RT planning CT scan will be performed in both DIBH and FB and two separate treatment plans will be calculated. The superior treatment plan, i.e. equal target coverage and lowest overall dose to the OARs, will be chosen for treatment. Patient comfort will be assessed daily by questionnaires and by adherence to the respiratory management procedure. Discussion: RT in DIBH is expected to diminish irradiation of the OARs surrounding the treatment target and thereby reduce the risk of late effects in childhood cancer survivors.Peer reviewe

    VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases

    No full text
    <div><p></p><p><b>Background.</b> Prostate cancer (PCa) patients with metastatic disease often suffer from skeletal pain and urinary retention impairing their quality of life. Prophylactic radiotherapy to bone metastases planned concomitantly with primary PCa radiotherapy could enable more precise control of combined dose in healthy tissues when compared to sequential palliative treatment.</p><p><b>Materials and methods.</b> Volumetric modulated arc therapy (VMAT) was planned for 14 PCa patients with primary bone metastases. The bone planning target volume (PTV<sub>bone</sub>) was contoured together with the PTVs of prostate (pr), pelvic lymph nodes (ln) and seminal vesicles (sv). Another virtual plan was calculated excluding PTV<sub>bone</sub> for dose volume histogram (DVH) comparison. DVHs were additionally compared to a set of actual VMAT treatment plans of a control cohort of 13 high risk PCa patients treated with PTV<sub>pr</sub>, PTV<sub>sv</sub> and PTV<sub>ln</sub>. The prescribed doses varied between 42 and 76 Gy for PTV<sub>bone</sub>.</p><p><b>Results.</b> Recommended healthy tissue tolerances (Quantec) were not exceeded except for one patient's rectum V<sub>50Gy</sub> value. Rectum doses did not increase significantly due to the inclusion of PTV<sub>bone</sub>. For bladder, there was a slight increase for V<sub>65Gy</sub> and V<sub>50Gy</sub> (2.7% and 7.4%). The DVHs of metastatic and non-metastatic patients were comparable. There were no differences in the PTV<sub>pr</sub> DVH parameters, while mean PTV<sub>ln</sub> dose increased by 3.7 Gy–4.4 Gy due to the increased treatment volume related to PTV<sub>bone</sub>. All side effects were < grade 3 during the mean follow-up duration of 25 months.</p><p><b>Conclusions.</b> VMAT offers a good optimization tool for adding extra PTVs to the radiotherapy plan. Radiotherapy of bone metastases concomitantly with irradiation of the primary prostate tumor is a safe and well-tolerated approach and deserves to be studied in a randomized setting.</p></div
    corecore